Zoetis Inc. (NYSE:ZTS) Shares Sold by First Hawaiian Bank

First Hawaiian Bank trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 37.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,314 shares of the company’s stock after selling 4,932 shares during the quarter. First Hawaiian Bank’s holdings in Zoetis were worth $1,441,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Focus Financial Network Inc. ADV purchased a new stake in shares of Zoetis during the fourth quarter worth about $2,159,000. Price T Rowe Associates Inc. MD raised its holdings in Zoetis by 31.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after acquiring an additional 3,244,074 shares during the last quarter. Ninety One UK Ltd lifted its stake in shares of Zoetis by 13.1% during the 4th quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock worth $21,374,000 after purchasing an additional 12,537 shares during the period. Axiom Investors LLC DE grew its position in shares of Zoetis by 36.3% in the fourth quarter. Axiom Investors LLC DE now owns 594,474 shares of the company’s stock valued at $117,331,000 after purchasing an additional 158,459 shares during the period. Finally, Global Assets Advisory LLC acquired a new position in Zoetis in the first quarter valued at $8,831,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have commented on ZTS. Stifel Nicolaus lifted their price target on Zoetis from $180.00 to $200.00 and gave the company a “buy” rating in a report on Monday. HSBC decreased their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Barclays cut their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. BTIG Research started coverage on Zoetis in a research note on Thursday, July 25th. They set a “buy” rating and a $220.00 price target for the company. Finally, The Goldman Sachs Group reduced their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research note on Monday, May 6th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $214.89.

Zoetis Stock Up 6.6 %

Shares of ZTS stock traded up $11.46 on Tuesday, hitting $186.28. The stock had a trading volume of 2,066,647 shares, compared to its average volume of 2,796,705. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The firm has a market capitalization of $85.00 billion, a price-to-earnings ratio of 36.44, a P/E/G ratio of 2.80 and a beta of 0.86. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The stock’s 50 day moving average is $175.53 and its 200-day moving average is $175.38.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.93%. Zoetis’s dividend payout ratio (DPR) is 33.33%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.